Tuzistra Xr Patent Expiration

Tuzistra Xr is a drug owned by Tris Pharma Inc. It is protected by 2 US drug patents filed in 2015 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2029. Details of Tuzistra Xr's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(4 years from now)

Active
US8790700 Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tuzistra Xr's patents.

Given below is the list of recent legal activities going on the following patents of Tuzistra Xr.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 12 Jan, 2022 US8790700
Payment of Maintenance Fee, 4th Year, Large Entity 18 Jan, 2018 US8790700
Application ready for PDX access by participating foreign offices 31 Aug, 2015 US8790700
Recordation of Patent Grant Mailed 29 Jul, 2014 US8790700
Patent Issue Date Used in PTA Calculation 29 Jul, 2014 US8790700
Email Notification 10 Jul, 2014 US8790700
Issue Notification Mailed 09 Jul, 2014 US8790700
Dispatch to FDC 28 Jun, 2014 US8790700
Application Is Considered Ready for Issue 19 Jun, 2014 US8790700
Printer Rush- No mailing 18 Jun, 2014 US8790700

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Tuzistra Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tuzistra Xr's family patents as well as insights into ongoing legal events on those patents.

Tuzistra Xr's Family Patents

Tuzistra Xr has patent protection in a total of 14 countries. It has a significant patent presence in the US with 59.5% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Tuzistra Xr.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Tuzistra Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 29, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Tuzistra Xr Generics:

There are no approved generic versions for Tuzistra Xr as of now.





About Tuzistra Xr

Tuzistra Xr is a drug owned by Tris Pharma Inc. Tuzistra Xr uses Chlorpheniramine Polistirex; Codeine Polistirex as an active ingredient. Tuzistra Xr was launched by Tris Pharma Inc in 2015.

Approval Date:

Tuzistra Xr was approved by FDA for market use on 30 April, 2015.

Active Ingredient:

Tuzistra Xr uses Chlorpheniramine Polistirex; Codeine Polistirex as the active ingredient. Check out other Drugs and Companies using Chlorpheniramine Polistirex; Codeine Polistirex ingredient

Dosage:

Tuzistra Xr is available in suspension, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML SUSPENSION, EXTENDED RELEASE Discontinued ORAL